TICKERNERD
Menu
AXSMAXSMHealthcare · Biotechnology

AXSM Stock Forecast: Axsome Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$221
+4.56% on the day

The 21 Wall Street analysts covering Axsome Therapeutics, Inc. hold a median 12-month price target of $280 — +26.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$11.6B
Ticker Nerd rank
74 / 100
Median analyst target
$280
Analysts covering
21
Revenue$218.4M+45.5% y/y
Operating income−$51.1M
Net income−$51.3M
Free cash flow−$33.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.0%
1M
+2.3%
YTD
+20.9%
1Y
+79.5%
From 52W high
−13.5%
From 52W low
+93.5%
$114
$255
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AXSM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Axsome Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
94
Quality
92
Value
90
Momentum
89
Accruals
64
Growth
59
Issuance
39
Revisions
38
Size
14

Volatility (94): The share price has been relatively steady.

Revisions (38): Analysts have, on balance, been cutting their forecasts.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AXSM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AXSM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250$300$350$400Oct 25Jan 26Apr 26Jul 26AXSMHigh $380Median $280Low $246

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
20 Buy1 Hold0 Sell
Low $246Median $280High $380

The green dot is the last close — the median target sits +26.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$290
12 Aug 2026MizuhoMaintainsOutperform$306 → $316
12 Aug 2026MizuhoMaintainsOutperform—
11 Aug 2026GuggenheimMaintainsBuy—
11 Aug 2026GuggenheimMaintainsBuy$260 → $275
11 Aug 2026Morgan StanleyMaintainsEqual-Weight$242 → $251
11 Aug 2026Morgan StanleyMaintainsEqual-Weight—
11 Aug 2026NeedhamMaintainsBuy—
11 Aug 2026NeedhamMaintainsBuy$267 → $268
11 Aug 2026RBC CapitalMaintainsOutperform—
11 Aug 2026RBC CapitalMaintainsOutperform$304 → $297
11 Aug 2026Wells FargoMaintainsOverweight—
11 Aug 2026Wells FargoMaintainsOverweight$255 → $256
31 July 2026MizuhoMaintainsOutperform$310 → $306
31 July 2026MizuhoMaintainsOutperform—
21 July 2026BMO CapitalInitiatesOutperform$310
21 July 2026BMO CapitalInitiatesOutperform—
15 July 2026HC Wainwright & Co.ReiteratesBuy$290
15 July 2026HC Wainwright & Co.ReiteratesBuy—
8 July 2026HC Wainwright & Co.ReiteratesBuy$290

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AXSM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AXSM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Axsome Therapeutics, Inc. returned +79.5% against +17.5% for the S&P 500, dividends included.

AXSM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Oct 25Jan 26Apr 26Jul 26AXSMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AXSM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
6
Fundamentals

Axsome Therapeutics, Inc. (AXSM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−60.0×

Cheaper than 99% of US stocks

Price / sales
14.9×

Cheaper than 11% of US stocks

Price / book
138.6×

Cheaper than 1% of US stocks

EV / EBITDA
−66.3×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
45.5%

Higher than 84% of US stocks

Earnings growth (YoY)
45.5%

Higher than 73% of US stocks

Gross margin
93.8%

Higher than 98% of US stocks

Operating margin
−23.4%

Higher than 21% of US stocks

Net margin
−24.7%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−245.1%

Higher than 6% of US stocks

Return on assets
−16.3%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Axsome Therapeutics, Inc. (AXSM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Axsome Therapeutics, Inc. has a market value of $11.6B and an enterprise value of $11.5B.

  • Revenue in the twelve months to 30 June 2026: $776.6M. The latest quarter grew 45.5% year on year.

  • Net income over the same four quarters: −$191.6M, a −24.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.75.

  • Free cash flow in the twelve months to 30 June 2026: −$72.0M.

  • Shares outstanding: 52.3M.

  • Trailing P/E: −60.0×; forward P/E: 43.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Axsome Therapeutics, Inc. employs 1,346 people — $577K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AXSM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AXSMAxsome Therapeutics, Inc.$11.6B
74
TECHBio-Techne Corp.$11.2B
94
ARWRArrowhead Pharmaceuticals, Inc.$11.6B
57
CORTCorcept Therapeutics, Inc.$12.1B
79
HALOHalozyme Therapeutics, Inc.$12.2B
97
MDGLMadrigal Pharmaceuticals, Inc.$12.3B
69
KRYSKrystal Biotech, Inc.$10.3B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Axsome Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AXSM news & analysis

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 11 Sept 2026neutral

The Motley Fool published a comparison piece examining Axsome Therapeutics and CRISPR Therapeutics as potential healthcare stock investments for 2026. The article notes Axsome is rapidly scaling revenue through its portfolio of central nervous system treatments, while CRISPR is advancing its first approved gene-editing therapy into the commercial stage.

Why it matters — The article highlights Axsome's revenue growth from its CNS treatment portfolio, which is relevant for AXSM watchers tracking the company's commercial traction heading into 2026.

Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Axsome Therapeutics, Inc. presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with the event's transcript published on Seeking Alpha. The presentation is part of the company's ongoing participation in investor and healthcare conferences.

Why it matters — AXSM watchers would care because the conference presentation provides investors with direct insights into the company's outlook and strategy from its management.

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 10 Sept 2026neutral

The Motley Fool published a comparison of Axsome Therapeutics and Viking Therapeutics as potential healthcare stock picks for 2026. It notes that Axsome has become a commercial-stage company with rapidly growing revenue from its central nervous system treatments, while Viking remains clinical-stage with potential in the obesity and metabolic disease markets.

Why it matters — This piece highlights Axsome's transition to a commercial-stage company with growing CNS-treatment revenue, providing context for investors tracking its commercial progress versus clinical-stage peers.

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 9 Sept 2026negative

Axsome Therapeutics reported earnings 30 days ago, and its stock has declined 3.7% since that report. The piece examines what may be next for the stock following the earnings announcement.

Why it matters — Axsome watchers would care because the article assesses the company's stock performance and outlook in the period following its latest earnings report.

FAQ

Frequently asked questions about AXSM stock

What is the AXSM stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Axsome Therapeutics, Inc. have a median 12-month price target of $280, with estimates ranging from $246 to $380. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AXSM stock a buy right now?

Of the 21 analysts covering Axsome Therapeutics, Inc., 20 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Axsome Therapeutics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AXSM?

As at 12 Sept 2026, Axsome Therapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (94 of 100).

Will AXSM stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +26.8% from the last close, and Ticker Nerd's factor model ranks Axsome Therapeutics, Inc. 74 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AXSM stock forecast for 2030?

No analyst covering Axsome Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $246 to $380 over the next 12 months.

How has AXSM stock performed over the past year?

Axsome Therapeutics, Inc. returned +79.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Axsome Therapeutics, Inc. do?

Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.

What is the latest news on AXSM?

The most recent item we track (The Motley Fool, 11 Sept 2026): "Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?". The Motley Fool published a comparison piece examining Axsome Therapeutics and CRISPR Therapeutics as potential healthcare stock investments for 2026. The article notes Axsome is rapidly scaling revenue through its portfolio of central nervous system treatments, while CRISPR is advancing its first approved gene-editing therapy into the commercial stage.

Company

About Axsome Therapeutics, Inc.

Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its marketed products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine. The company also maintains a neuroscience pipeline spanning additional neurological and psychiatric conditions, reflecting its emphasis on disorders with limited treatment options. Axsome Therapeutics Inc. plays a specialized role in the healthcare market by combining commercial products with ongoing clinical development in psychiatry, sleep medicine, pain, and migraine care. Based in New York, the company is positioned as a focused CNS innovator serving patients, physicians, and healthcare systems with therapies designed to address unmet medical needs.

CEO Dr. Herriot Tabuteau M.D. · 1,346 employees · United States · https://www.axsome.com